25 XP   0   0   10

Fennec Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Fennec Pharmaceuticals Inc together

PenkeI guess you are interested in Fennec Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Fennec Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Fennec Pharmaceuticals Inc

I send you an email if I find something interesting about Fennec Pharmaceuticals Inc.

Quick analysis of Fennec Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Fennec Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$-0.43
Expected worth in 1 year
$-0.76
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-0.33
Return On Investment
-3.5%

For what price can you sell your share?

Current Price per Share
$9.38
Expected price per share
$7.44 - $11.92
How sure are you?
50%

1. Valuation of Fennec Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$9.38

Intrinsic Value Per Share

$-7.50 - $-5.73

Total Value Per Share

$-7.93 - $-6.16

2. Growth of Fennec Pharmaceuticals Inc (5 min.)




Is Fennec Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$11.5m$5.3m-$15.1m-154.4%

How much money is Fennec Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$4.4m-$6.1m$1.7m40.1%
Net Profit Margin-168.8%-126.9%--

How much money comes from the company's main activities?

3. Financial Health of Fennec Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#954 / 1011

Most Revenue
#343 / 1011

Most Profit
#404 / 1011

Most Efficient
#618 / 1011

What can you expect buying and holding a share of Fennec Pharmaceuticals Inc? (5 min.)

Welcome investor! Fennec Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Fennec Pharmaceuticals Inc.

What can you expect buying and holding a share of Fennec Pharmaceuticals Inc?

First you should know what it really means to hold a share of Fennec Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Fennec Pharmaceuticals Inc is $9.38. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Fennec Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Fennec Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.43. Based on the TTM, the Book Value Change Per Share is $-0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Fennec Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.10-1.1%-0.15-1.6%-0.22-2.3%-0.16-1.7%-0.11-1.2%
Usd Book Value Change Per Share-0.04-0.4%-0.08-0.9%-0.17-1.8%-0.06-0.6%-0.01-0.1%
Usd Dividend Per Share0.000.0%0.000.0%0.181.9%0.040.4%0.020.2%
Usd Total Gains Per Share-0.04-0.4%-0.08-0.9%0.010.1%-0.02-0.3%0.010.1%
Usd Price Per Share11.22-8.97-7.22-7.00-5.82-
Price to Earnings Ratio-27.52--18.74--8.48--12.23--15.30-
Price-to-Total Gains Ratio-294.12--173.46--31.88--73.22--82.70-
Price to Book Ratio-26.24--25.18-1.72-0.85-18.89-
Price-to-Total Gains Ratio-294.12--173.46--31.88--73.22--82.70-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.38
Number of shares106
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.04
Usd Book Value Change Per Share-0.08-0.06
Usd Total Gains Per Share-0.08-0.02
Gains per Quarter (106 shares)-8.81-2.63
Gains per Year (106 shares)-35.26-10.52
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-35-4515-26-21
20-71-8031-52-32
30-106-11546-77-43
40-141-15061-103-54
50-176-18576-129-65
60-212-22092-155-76
70-247-255107-180-87
80-282-290122-206-98
90-317-325137-232-109
100-353-360153-258-120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%3.037.00.07.5%10.081.01.010.9%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%8.032.00.020.0%25.064.03.027.2%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.090.02.2%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%9.031.00.022.5%26.063.03.028.3%

Fundamentals of Fennec Pharmaceuticals Inc

About Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fundamental data was last updated by Penke on 2024-04-11 07:47:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Fennec Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Fennec Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Fennec Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -27.6% means that $-0.28 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Fennec Pharmaceuticals Inc:

  • The MRQ is -27.6%. The company is making a huge loss. -2
  • The TTM is -168.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-27.6%TTM-168.8%+141.2%
TTM-168.8%YOY-126.9%-41.9%
TTM-168.8%5Y-154.4%-14.4%
5Y-154.4%10Y-77.2%-77.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.6%-196.1%+168.5%
TTM-168.8%-211.9%+43.1%
YOY-126.9%-277.7%+150.8%
5Y-154.4%-432.9%+278.5%
10Y-77.2%-599.3%+522.1%
1.1.2. Return on Assets

Shows how efficient Fennec Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Fennec Pharmaceuticals Inc to the Biotechnology industry mean.
  • -10.3% Return on Assets means that Fennec Pharmaceuticals Inc generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Fennec Pharmaceuticals Inc:

  • The MRQ is -10.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.3%TTM-20.8%+10.5%
TTM-20.8%YOY-27.0%+6.2%
TTM-20.8%5Y-20.6%-0.2%
5Y-20.6%10Y-22.4%+1.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.3%-13.3%+3.0%
TTM-20.8%-12.7%-8.1%
YOY-27.0%-11.8%-15.2%
5Y-20.6%-14.0%-6.6%
10Y-22.4%-15.9%-6.5%
1.1.3. Return on Equity

Shows how efficient Fennec Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Fennec Pharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Fennec Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Fennec Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-95.2%+95.2%
TTM-5Y-32.1%+32.1%
5Y-32.1%10Y-21.9%-10.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.0%+16.0%
YOY-95.2%-15.1%-80.1%
5Y-32.1%-19.7%-12.4%
10Y-21.9%-20.5%-1.4%

1.2. Operating Efficiency of Fennec Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Fennec Pharmaceuticals Inc is operating .

  • Measures how much profit Fennec Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Fennec Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -19.4% means the company generated $-0.19  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Fennec Pharmaceuticals Inc:

  • The MRQ is -19.4%. The company is operating very inefficient. -2
  • The TTM is -123.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-19.4%TTM-123.0%+103.7%
TTM-123.0%YOY-99.9%-23.1%
TTM-123.0%5Y-131.2%+8.1%
5Y-131.2%10Y-65.6%-65.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.4%-290.9%+271.5%
TTM-123.0%-224.4%+101.4%
YOY-99.9%-288.3%+188.4%
5Y-131.2%-479.5%+348.3%
10Y-65.6%-625.2%+559.6%
1.2.2. Operating Ratio

Measures how efficient Fennec Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.19 means that the operating costs are $1.19 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Fennec Pharmaceuticals Inc:

  • The MRQ is 1.187. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.241. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.187TTM2.241-1.054
TTM2.241YOY1.249+0.992
TTM2.2415Y1.732+0.509
5Y1.73210Y0.866+0.866
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1873.110-1.923
TTM2.2413.266-1.025
YOY1.2493.783-2.534
5Y1.7325.657-3.925
10Y0.8667.783-6.917

1.3. Liquidity of Fennec Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Fennec Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.56 means the company has $3.56 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Fennec Pharmaceuticals Inc:

  • The MRQ is 3.556. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.726. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.556TTM4.726-1.170
TTM4.726YOY7.544-2.819
TTM4.7265Y10.565-5.839
5Y10.56510Y9.753+0.812
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5563.905-0.349
TTM4.7264.212+0.514
YOY7.5445.337+2.207
5Y10.5656.062+4.503
10Y9.7536.401+3.352
1.3.2. Quick Ratio

Measures if Fennec Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Fennec Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 2.92 means the company can pay off $2.92 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Fennec Pharmaceuticals Inc:

  • The MRQ is 2.924. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.212. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.924TTM4.212-1.288
TTM4.212YOY7.279-3.067
TTM4.2125Y10.185-5.973
5Y10.18510Y9.519+0.667
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9243.572-0.648
TTM4.2124.001+0.211
YOY7.2795.364+1.915
5Y10.1856.009+4.176
10Y9.5196.287+3.232

1.4. Solvency of Fennec Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Fennec Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Fennec Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.43 means that Fennec Pharmaceuticals Inc assets are financed with 143.3% credit (debt) and the remaining percentage (100% - 143.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Fennec Pharmaceuticals Inc:

  • The MRQ is 1.433. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.456. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.433TTM1.456-0.023
TTM1.456YOY0.700+0.756
TTM1.4565Y0.514+0.941
5Y0.51410Y0.739-0.224
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4330.336+1.097
TTM1.4560.334+1.122
YOY0.7000.271+0.429
5Y0.5140.366+0.148
10Y0.7390.389+0.350
1.4.2. Debt to Equity Ratio

Measures if Fennec Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Fennec Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Fennec Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY2.802-2.802
TTM-5Y0.664-0.664
5Y0.66410Y0.545+0.118
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.382-0.382
TTM-0.397-0.397
YOY2.8020.341+2.461
5Y0.6640.432+0.232
10Y0.5450.465+0.080

2. Market Valuation of Fennec Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Fennec Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Fennec Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -27.52 means the investor is paying $-27.52 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Fennec Pharmaceuticals Inc:

  • The EOD is -23.007. Based on the earnings, the company is expensive. -2
  • The MRQ is -27.520. Based on the earnings, the company is expensive. -2
  • The TTM is -18.743. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-23.007MRQ-27.520+4.513
MRQ-27.520TTM-18.743-8.777
TTM-18.743YOY-8.478-10.264
TTM-18.7435Y-12.232-6.510
5Y-12.23210Y-15.300+3.068
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-23.007-2.262-20.745
MRQ-27.520-2.599-24.921
TTM-18.743-2.674-16.069
YOY-8.478-4.133-4.345
5Y-12.232-6.258-5.974
10Y-15.300-6.171-9.129
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Fennec Pharmaceuticals Inc:

  • The EOD is -12.746. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -15.246. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -14.763. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.746MRQ-15.246+2.500
MRQ-15.246TTM-14.763-0.483
TTM-14.763YOY-11.213-3.550
TTM-14.7635Y-13.714-1.049
5Y-13.71410Y-24.895+11.181
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.746-2.913-9.833
MRQ-15.246-3.275-11.971
TTM-14.763-3.508-11.255
YOY-11.213-5.620-5.593
5Y-13.714-8.306-5.408
10Y-24.895-8.854-16.041
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Fennec Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -26.24 means the investor is paying $-26.24 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Fennec Pharmaceuticals Inc:

  • The EOD is -21.936. Based on the equity, the company is expensive. -2
  • The MRQ is -26.239. Based on the equity, the company is expensive. -2
  • The TTM is -25.181. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-21.936MRQ-26.239+4.303
MRQ-26.239TTM-25.181-1.058
TTM-25.181YOY1.720-26.901
TTM-25.1815Y0.847-26.028
5Y0.84710Y18.890-18.043
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-21.9361.858-23.794
MRQ-26.2392.090-28.329
TTM-25.1812.091-27.272
YOY1.7202.866-1.146
5Y0.8473.488-2.641
10Y18.8903.836+15.054
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Fennec Pharmaceuticals Inc.

3.1. Institutions holding Fennec Pharmaceuticals Inc

Institutions are holding 55.159% of the shares of Fennec Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Southpoint Capital Advisors LP15.26510.9827407721400
2023-12-31Sonic GP LLC9.013131.0265240735700
2023-12-31Solas Capital Management LLC5.16119.60321378513-347054-20.1125
2023-12-31venBio Select Advisor LLC4.49280.186120000000
2023-12-31Vanguard Group Inc4.26840.0003114006310582951294.2655
2023-12-31DG Capital Management, LLC4.02727.45981075634-67465-5.9019
2023-12-31BlackRock Inc3.49910.00039345918955010.5971
2023-12-31Harbert Fund Advisors Inc1.7483.590446686900
2023-12-31AIGH Capital Management, LLC1.23321.462329370-44156-11.8214
2023-12-31Gendell Jeffrey L1.05760.1723282478-3514-1.2287
2023-12-31State Street Corporation0.99460.000126565042161.6126
2023-12-31Geode Capital Management, LLC0.81840.0003218590123916.0092
2023-12-31Worth Venture Partners, LLC0.52980.8581415004886452.7484
2023-12-31683 Capital Management LLC0.52420.1287140000-160000-53.3333
2023-12-31Northern Trust Corp0.41840.00021117608970.8091
2023-12-31Lion Point Capital, LP0.41180.617511000000
2023-12-31Morgan Stanley - Brokerage Accounts0.28880.0001771393467981.6745
2023-12-31CIBC World Markets Inc.0.26940.002171965-7219-9.1167
2023-12-31EAM Investors, LLC0.24630.13165795657950
2023-12-31Goldman Sachs Group Inc0.23210.00016200044664257.6373
Total 54.499456.221614556488+729943+5.0%

3.2. Funds holding Fennec Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv3.70480.0006100400000
2024-03-28iShares Russell 2000 ETF1.54220.00714179452010.0481
2024-01-31Fidelity Small Cap Index0.67490.007418288617650.9745
2024-03-28iShares Russell 2000 Value ETF0.46110.0111124967-79-0.0632
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.39930.002510820000
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.24690.00766690000
2024-02-29Vanguard Russell 2000 ETF0.24070.00656524352418.7347
2023-12-31NT R2000 Index Fund - NL0.18210.007649337-796-1.5878
2024-02-29Schwab Small Cap Index0.15310.00674149700
2024-03-28iShares Micro-Cap ETF0.14760.0484400028972.2938
2024-03-28iShares Russell 2000 Growth ETF0.14590.003839537-46-0.1162
2023-12-31NT R2000 Index Fund - DC - NL - 20.14340.007638853-779-1.9656
2023-12-31NT R2000 Value Index Fund - NL0.13370.010836240-873-2.3523
2023-12-31Pleiades Small Cap Equity A0.13190.044535732357320
2024-02-29iShares Russell 2000 Small-Cap Idx Instl0.12870.00723489100
2024-03-31Russell 2000 Index Non-Lendable Fund E0.1160.0068314272030.6501
2024-02-29Vanguard Balanced Index Inv0.11220.00053040000
2023-12-31Northern Trust Russell 2000 Value Index0.09870.011626754300612.6579
2023-12-31NT R2000 Value Index Fund - L0.09870.011526754300612.6579
2024-03-31BlackRock Russell 2500™ Index F0.09350.002825347100.0395
Total 8.95540.21262426912+47488+2.0%

3.3. Insider Transactions

Insiders are holding 16.965% of the shares of Fennec Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-05Rosty RaykovSELL4430010.75
2024-04-03Rosty RaykovSELL4058410.78
2024-03-26Chris A RallisSELL211410.97
2024-03-25Robert AndradeSELL1397511
2024-01-04Robert AndradeSELL1500010.64
2023-12-28Rosty RaykovSELL365611.55
2023-12-26Chris A RallisSELL139010.9
2023-11-20Chris A RallisSELL2698.25
2023-11-08Rosty RaykovSELL250447.76
2023-08-18Chris A RallisSELL6737.85
2023-07-24Chris A RallisSELL67968.17
2023-07-06Chris A RallisSELL22078.47
2023-06-30Robert AndradeSELL75008.82
2023-06-28Robert AndradeSELL100008.99
2023-05-19Chris A RallisSELL17587.36

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Fennec Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.038-0.083+118%-0.170+345%-0.061+59%-0.009-76%
Book Value Per Share---0.428-0.362-15%0.197-317%0.428-200%0.350-222%
Current Ratio--3.5564.726-25%7.544-53%10.565-66%9.753-64%
Debt To Asset Ratio--1.4331.456-2%0.700+105%0.514+178%0.739+94%
Debt To Equity Ratio----0%2.802-100%0.664-100%0.545-100%
Dividend Per Share----0%0.180-100%0.036-100%0.018-100%
Eps---0.102-0.149+46%-0.219+115%-0.163+60%-0.108+6%
Free Cash Flow Per Share---0.184-0.159-13%-0.167-9%-0.137-25%-0.084-54%
Free Cash Flow To Equity Per Share--0.032-0.097+404%0.025+29%0.042-25%0.051-37%
Gross Profit Margin--2.4031.994+21%1.089+121%1.217+98%1.108+117%
Intrinsic Value_10Y_max---5.733--------
Intrinsic Value_10Y_min---7.504--------
Intrinsic Value_1Y_max---0.372--------
Intrinsic Value_1Y_min---0.638--------
Intrinsic Value_3Y_max---1.273--------
Intrinsic Value_3Y_min---2.028--------
Intrinsic Value_5Y_max---2.359--------
Intrinsic Value_5Y_min---3.527--------
Market Cap253638014.000-20%303392166.000242551491.000+25%195230966.000+55%189322660.450+60%157315395.344+93%
Net Profit Margin---0.276-1.688+513%-1.269+361%-1.544+460%-0.772+180%
Operating Margin---0.194-1.230+535%-0.999+416%-1.312+577%-0.656+239%
Operating Ratio--1.1872.241-47%1.249-5%1.732-31%0.866+37%
Pb Ratio-21.936+16%-26.239-25.181-4%1.720-1626%0.847-3199%18.890-239%
Pe Ratio-23.007+16%-27.520-18.743-32%-8.478-69%-12.232-56%-15.300-44%
Price Per Share9.380-20%11.2208.970+25%7.220+55%7.002+60%5.818+93%
Price To Free Cash Flow Ratio-12.746+16%-15.246-14.763-3%-11.213-26%-13.714-10%-24.895+63%
Price To Total Gains Ratio-245.883+16%-294.116-173.461-41%-31.883-89%-73.224-75%-82.702-72%
Quick Ratio--2.9244.212-31%7.279-60%10.185-71%9.519-69%
Return On Assets---0.103-0.208+101%-0.270+162%-0.206+100%-0.224+117%
Return On Equity----0%-0.9520%-0.3210%-0.2190%
Total Gains Per Share---0.038-0.083+118%0.010-469%-0.025-35%0.009-541%
Usd Book Value---11562539.000-9789884.750-15%5324500.000-317%11576923.050-200%9474236.525-222%
Usd Book Value Change Per Share---0.038-0.083+118%-0.170+345%-0.061+59%-0.009-76%
Usd Book Value Per Share---0.428-0.362-15%0.197-317%0.428-200%0.350-222%
Usd Dividend Per Share----0%0.180-100%0.036-100%0.018-100%
Usd Eps---0.102-0.149+46%-0.219+115%-0.163+60%-0.108+6%
Usd Free Cash Flow---4974950.000-4307007.750-13%-4514500.000-9%-3708151.550-25%-2282875.775-54%
Usd Free Cash Flow Per Share---0.184-0.159-13%-0.167-9%-0.137-25%-0.084-54%
Usd Free Cash Flow To Equity Per Share--0.032-0.097+404%0.025+29%0.042-25%0.051-37%
Usd Market Cap253638014.000-20%303392166.000242551491.000+25%195230966.000+55%189322660.450+60%157315395.344+93%
Usd Price Per Share9.380-20%11.2208.970+25%7.220+55%7.002+60%5.818+93%
Usd Profit---2756126.000-4424781.500+61%-6199500.000+125%-4536356.300+65%-2832128.150+3%
Usd Revenue--10004060.0005380265.000+86%383750.000+2507%1161303.000+761%580651.500+1623%
Usd Total Gains Per Share---0.038-0.083+118%0.010-469%-0.025-35%0.009-541%
 EOD+2 -6MRQTTM+22 -10YOY+20 -155Y+18 -1710Y+14 -21

4.2. Fundamental Score

Let's check the fundamental score of Fennec Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-23.007
Price to Book Ratio (EOD)Between0-1-21.936
Net Profit Margin (MRQ)Greater than0-0.276
Operating Margin (MRQ)Greater than0-0.194
Quick Ratio (MRQ)Greater than12.924
Current Ratio (MRQ)Greater than13.556
Debt to Asset Ratio (MRQ)Less than11.433
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.103
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Fennec Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.219
Ma 20Greater thanMa 5010.529
Ma 50Greater thanMa 10010.059
Ma 100Greater thanMa 20010.059
OpenGreater thanClose9.340
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets26,727
Total Liabilities38,289
Total Stockholder Equity-11,563
 As reported
Total Liabilities 38,289
Total Stockholder Equity+ -11,563
Total Assets = 26,727

Assets

Total Assets26,727
Total Current Assets26,721
Long-term Assets6
Total Current Assets
Cash And Cash Equivalents 13,201
Net Receivables 8,769
Inventory 2,145
Other Current Assets 2,606
Total Current Assets  (as reported)26,721
Total Current Assets  (calculated)26,721
+/- 0
Long-term Assets
Long-term Assets Other 6
Long-term Assets  (as reported)6
Long-term Assets  (calculated)6
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,514
Long-term Liabilities30,775
Total Stockholder Equity-11,563
Total Current Liabilities
Short-term Debt 21
Accounts payable 3,759
Other Current Liabilities 3,735
Total Current Liabilities  (as reported)7,514
Total Current Liabilities  (calculated)7,514
+/- 0
Long-term Liabilities
Long term Debt 30,931
Capital Lease Obligations Min Short Term Debt2
Long-term Liabilities  (as reported)30,775
Long-term Liabilities  (calculated)30,933
+/- 158
Total Stockholder Equity
Common Stock143,569
Retained Earnings -218,123
Accumulated Other Comprehensive Income 1,237
Other Stockholders Equity 61,755
Total Stockholder Equity (as reported)-11,563
Total Stockholder Equity (calculated)-11,563
+/-0
Other
Capital Stock144,307
Cash and Short Term Investments 13,201
Common Stock Shares Outstanding 26,833
Current Deferred Revenue0
Liabilities and Stockholders Equity 26,727
Net Debt 16,382
Net Invested Capital 19,309
Net Working Capital 19,305
Short Long Term Debt Total 29,583



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-30
> Total Assets 
643
0
6,052
0
10,455
9,098
8,469
7,624
6,817
5,680
23,271
22,893
25,660
23,725
39,610
36,045
41,734
41,150
35,448
32,457
36,132
28,445
24,668
26,413
22,439
16,584
16,584
21,665
19,460
17,209
14,203
11,195
8,658
6,060
3,247
1,699
1,699
833
470
7,156
7
5,993
7,637
6,830
6,271
5,351
4,757
3,600
2,930
2,365
2,365
1,030
640
1,752
1,395
1,049
673
2,372
1,949
1,871
1,450
1,019
588
5,104
4,580
3,972
3,288
10,259
9,888
28,401
26,836
25,704
24,935
22,950
20,657
17,829
15,907
14,146
10,368
39,316
34,070
31,417
27,825
28,115
26,014
22,414
19,149
15,568
30,417
26,939
21,821
19,437
19,028
26,727
26,72719,02819,43721,82126,93930,41715,56819,14922,41426,01428,11527,82531,41734,07039,31610,36814,14615,90717,82920,65722,95024,93525,70426,83628,4019,88810,2593,2883,9724,5805,1045881,0191,4501,8711,9492,3726731,0491,3951,7526401,0302,3652,3652,9303,6004,7575,3516,2716,8307,6375,99377,1564708331,6991,6993,2476,0608,65811,19514,20317,20919,46021,66516,58416,58422,43926,41324,66828,44536,13232,45735,44841,15041,73436,04539,61023,72525,66022,89323,2715,6806,8177,6248,4699,09810,45506,0520643
   > Total Current Assets 
0
0
5,686
0
9,935
8,592
7,913
7,025
6,184
5,000
3,150
1,787
3,333
2,076
17,573
14,940
21,675
20,555
15,122
12,872
16,903
13,399
10,199
12,525
9,147
5,895
5,895
20,967
18,784
16,561
13,637
10,701
8,201
5,639
3,247
1,699
1,699
833
470
7,156
7
5,993
7,637
6,830
6,271
5,351
4,757
3,600
2,930
2,365
2,365
1,030
640
1,752
1,395
1,049
673
2,372
1,949
1,871
1,450
1,019
588
5,104
4,580
3,972
3,288
10,259
9,888
28,401
26,836
25,704
24,935
22,950
20,343
17,532
15,627
13,884
10,123
38,899
34,070
31,417
27,825
28,074
25,979
22,387
19,128
15,554
30,153
26,728
21,662
19,331
18,946
26,721
26,72118,94619,33121,66226,72830,15315,55419,12822,38725,97928,07427,82531,41734,07038,89910,12313,88415,62717,53220,34322,95024,93525,70426,83628,4019,88810,2593,2883,9724,5805,1045881,0191,4501,8711,9492,3726731,0491,3951,7526401,0302,3652,3652,9303,6004,7575,3516,2716,8307,6375,99377,1564708331,6991,6993,2475,6398,20110,70113,63716,56118,78420,9675,8955,8959,14712,52510,19913,39916,90312,87215,12220,55521,67514,94017,5732,0763,3331,7873,1505,0006,1847,0257,9138,5929,93505,68600
       Cash And Cash Equivalents 
0
0
5,268
0
9,351
8,096
7,263
6,565
207
4,453
2,486
970
2,151
954
16,567
14,182
13,673
12,118
14,703
12,553
13,172
11,969
9,509
12,265
8,950
5,665
5,665
20,611
13,307
16,162
13,298
10,378
7,882
5,349
3,047
1,540
1,540
685
348
7,152
7
5,947
5,023
6,810
6,174
5,297
4,719
3,586
2,860
2,303
2,303
1,007
538
1,663
1,338
1,015
593
2,307
1,916
1,854
1,366
942
545
5,081
4,537
3,926
3,251
10,232
9,688
28,260
26,719
25,640
24,524
22,781
20,231
17,475
15,240
13,650
9,901
38,729
33,166
30,344
26,751
27,293
24,335
21,100
18,259
14,915
29,752
23,774
18,390
14,958
12,399
13,201
13,20112,39914,95818,39023,77429,75214,91518,25921,10024,33527,29326,75130,34433,16638,7299,90113,65015,24017,47520,23122,78124,52425,64026,71928,2609,68810,2323,2513,9264,5375,0815459421,3661,8541,9162,3075931,0151,3381,6635381,0072,3032,3032,8603,5864,7195,2976,1746,8105,0235,94777,1523486851,5401,5403,0475,3497,88210,37813,29816,16213,30720,6115,6655,6658,95012,2659,50911,96913,17212,55314,70312,11813,67314,18216,5679542,1519702,4864,4532076,5657,2638,0969,35105,26800
       Short-term Investments 
0
0
0
0
0
0
0
0
5,368
0
0
0
0
0
0
0
7,110
7,550
0
0
3,435
1,175
391
0
0
0
0
0
5,039
0
0
0
0
0
52
53
54
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000000000000000000000545352000005,039000003911,1753,435007,5507,11000000005,36800000000
       Net Receivables 
0
0
123
0
135
129
203
87
138
94
66
127
22
30
45
54
39
52
19
178
164
144
145
91
90
103
103
214
206
185
202
188
182
139
139
0
0
69
43
0
1
0
2,548
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,545
1,683
2,445
4,525
8,769
8,7694,5252,4451,6831,54500000000000000000000000000000000000000000000002,548010436900139139182188202185206214103103909114514416417819523954453022127669413887203129135012300
       Inventory 
0
0
0
0
0
37
136
62
252
245
324
330
329
315
501
419
151
79
84
90
102
59
103
119
84
94
94
114
204
185
109
107
109
123
0
0
0
75
75
0
0
0
29
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
576
918
1,439
1,755
2,145
2,1451,7551,439918576000000000000000000000000000000000000000000000029000757500012310910710918520411494948411910359102908479151419501315329330324245252621363700000
   > Long-term Assets 
0
0
366
0
520
506
556
599
633
680
20,121
21,106
22,327
21,649
22,037
21,106
20,059
20,594
20,326
19,585
19,229
15,046
14,469
13,887
13,292
10,689
10,689
698
676
648
566
494
457
421
421
0
0
0
0
0
0
46
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65
0
0
0
0
0
0
0
46
0
0
0
141
0
0
0
169
314
297
280
262
245
417
0
1,073
0
41
35
27
21
14
264
211
159
106
82
6
682106159211264142127354101,0730417245262280297314169000141000460000000650000000000000004600000042142145749456664867669810,68910,68913,29213,88714,46915,04619,22919,58520,32620,59420,05921,10622,03721,64922,32721,10620,121680633599556506520036600
       Property Plant Equipment 
207
0
366
0
520
506
556
599
633
576
541
533
486
463
448
362
420
456
583
521
318
892
859
821
769
293
293
296
294
648
566
494
457
421
421
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29
0
02900000000000000000000000000000000000000000000000000000000042142145749456664829429629329376982185989231852158345642036244846348653354157663359955650652003660207
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
19,592
20,443
21,718
21,047
21,497
20,518
19,604
20,122
19,735
19,056
18,373
14,154
13,610
13,065
12,522
9,956
9,956
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000000000009,9569,95612,52213,06513,61014,15418,37319,05619,73520,12219,60420,51821,49721,04721,71820,44319,5920000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
103
19,592
20,587
0
0
21,443
20,773
19,641
0
0
19,063
0
14,672
14,109
0
12,982
10,396
0
0
0
363
343
324
0
285
0
0
0
0
0
0
0
-46
2,614
20
97
0
38
14
70
0
42
23
102
0
57
34
80
-65
33
17
84
0
43
23
43
-46
37
27
200
-141
117
64
0
-169
314
297
280
262
245
417
0
-1,073
0
41
35
27
21
14
264
211
0
106
0
0
00106021126414212735410-1,0730417245262280297314-169064117-1412002737-464323430841733-65803457010223420701438097202,614-460000000285032434336300010,39612,982014,10914,672019,0630019,64120,77321,4430020,58719,592103000000000
> Total Liabilities 
596
0
533
0
635
544
527
572
736
986
8,071
8,304
10,349
10,027
9,199
8,577
8,732
8,816
8,917
9,769
9,313
8,388
7,990
7,752
8,626
8,999
8,999
2,192
2,830
3,061
3,026
3,019
3,504
3,007
2,139
1,297
1,297
427
430
7,632
0
10,917
7,922
7,514
9,941
5,471
2,162
1,555
1,646
7,322
7,322
3,459
4,767
3,207
5,729
5,707
3,901
1,759
1,123
759
431
471
345
451
360
402
427
580
1,030
1,644
1,173
847
2,076
1,637
1,451
1,353
905
2,271
1,907
3,190
2,885
2,347
2,892
5,834
7,001
6,642
6,625
7,027
27,615
29,508
29,160
29,164
29,559
38,289
38,28929,55929,16429,16029,50827,6157,0276,6256,6427,0015,8342,8922,3472,8853,1901,9072,2719051,3531,4511,6372,0768471,1731,6441,0305804274023604513454714317591,1231,7593,9015,7075,7293,2074,7673,4597,3227,3221,6461,5552,1625,4719,9417,5147,92210,91707,6324304271,2971,2972,1393,0073,5043,0193,0263,0612,8302,1928,9998,9998,6267,7527,9908,3889,3139,7698,9178,8168,7328,5779,19910,02710,3498,3048,07198673657252754463505330596
   > Total Current Liabilities 
480
0
444
0
525
458
459
518
694
960
889
691
1,088
857
1,216
966
1,475
1,376
1,581
2,700
2,094
2,664
2,416
2,354
3,407
4,695
4,695
1,483
2,109
2,402
2,389
2,403
2,904
2,430
1,593
745
745
420
423
370
0
10,917
7,922
7,514
9,941
5,471
2,162
1,555
1,646
7,322
7,322
3,459
4,767
3,207
5,729
5,707
3,901
1,759
1,123
759
431
471
345
451
360
402
427
580
1,030
1,644
1,173
847
2,076
1,637
1,451
1,353
905
2,271
1,907
3,190
2,885
2,347
2,892
848
2,014
1,654
2,136
3,037
2,927
4,609
4,020
3,778
3,913
7,514
7,5143,9133,7784,0204,6092,9273,0372,1361,6542,0148482,8922,3472,8853,1901,9072,2719051,3531,4511,6372,0768471,1731,6441,0305804274023604513454714317591,1231,7593,9015,7075,7293,2074,7673,4597,3227,3221,6461,5552,1625,4719,9417,5147,92210,91703704234207457451,5932,4302,9042,4032,3892,4022,1091,4834,6954,6953,4072,3542,4162,6642,0942,7001,5811,3761,4759661,2168571,08869188996069451845945852504440480
       Short-term Debt 
0
0
25
0
25
24
56
0
0
57
0
0
0
170
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,244
9,465
0
0
0
0
0
0
0
0
2,863
5,518
5,336
3,499
1,319
694
309
93
82
39
56
37
33
71
190
373
167
0
0
0
0
0
0
0
0
0
0
0
0
0
-14
-13
-12
500
1,000
0
0
0
0
21
21
212100001,000500-12-13-140000000000000167373190713337563982933096941,3193,4995,3365,5182,863000000009,4657,24400000000000000000000000000000170000570056242502500
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,319
0
0
0
82
0
0
0
33
71
190
373
167
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
1,000
0
0
0
0
0
0
0000001,00050000000000000000001673731907133000820001,319000000000000000000000000000000000000000000000000000000000
       Accounts payable 
424
0
389
0
441
378
402
462
635
904
846
632
1,040
657
1,202
966
1,475
1,376
1,581
1,467
1,116
1,385
1,085
655
1,121
2,074
2,074
457
541
532
513
649
990
547
686
151
151
318
338
294
295
272
442
239
414
342
374
276
315
259
259
716
315
212
154
335
364
308
384
401
252
297
225
345
235
244
224
296
492
855
1,033
709
1,866
1,032
1,298
1,228
788
1,612
1,675
2,755
2,684
1,571
2,508
677
1,154
777
1,224
1,743
2,533
2,390
2,947
3,005
2,941
3,759
3,7592,9413,0052,9472,3902,5331,7431,2247771,1546772,5081,5712,6842,7551,6751,6127881,2281,2981,0321,8667091,0338554922962242442353452252972524013843083643351542123157162592593152763743424142394422722952943383181511516865479906495135325414572,0742,0741,1216551,0851,3851,1161,4671,5811,3761,4759661,2026571,04063284690463546240237844103890424
       Other Current Liabilities 
30
0
30
0
59
57
56
56
59
57
43
59
48
30
15
0
0
0
0
1,233
978
1,279
1,331
1,699
2,286
2,621
2,621
1,026
1,568
1,870
1,876
1,754
1,914
1,883
907
594
594
102
85
65
-295
10,645
7,480
7,275
9,527
5,129
1,788
1,279
1,331
7,063
7,063
2,743
4,452
2,995
5,575
5,372
3,537
1,451
739
358
179
174
120
106
125
158
203
284
538
789
140
138
210
605
153
125
117
659
232
435
201
776
384
171
860
877
412
294
394
2,219
1,073
773
951
3,735
3,7359517731,0732,2193942944128778601713847762014352326591171251536052101381407895382842031581251061201741793587391,4513,5375,3725,5752,9954,4522,7437,0637,0631,3311,2791,7885,1299,5277,2757,48010,645-29565851025945949071,8831,9141,7541,8761,8701,5681,0262,6212,6212,2861,6991,3311,2799781,23300001530485943575956565759030030
   > Long-term Liabilities 
0
0
89
0
110
85
68
54
42
26
7,183
7,613
9,261
9,170
7,982
7,611
7,257
7,440
7,336
7,069
7,219
5,724
5,574
5,398
5,219
4,304
4,304
709
721
659
637
616
600
577
546
0
552
7
7
0
0
272
442
239
414
342
374
276
315
0
259
716
315
212
154
335
364
308
384
401
252
297
225
345
235
244
224
296
492
855
1,033
709
1,866
1,032
1,298
1,228
788
1,612
1,675
2,755
2,684
1,571
2,508
4,986
4,987
4,988
4,489
3,990
24,688
24,899
25,140
25,386
25,646
30,775
30,77525,64625,38625,14024,89924,6883,9904,4894,9884,9874,9862,5081,5712,6842,7551,6751,6127881,2281,2981,0321,8667091,0338554922962242442353452252972524013843083643351542123157162590315276374342414239442272007755205465776006166376597217094,3044,3045,2195,3985,5745,7247,2197,0697,3367,4407,2577,6117,9829,1709,2617,6137,183264254688511008900
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,986
4,987
4,988
4,489
3,990
24,688
0
24,659
24,679
0
0
0024,67924,659024,6883,9904,4894,9884,9874,98600000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
-25
0
-25
-24
-56
0
0
-57
0
0
0
-170
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-7,244
-9,465
0
0
0
0
0
0
0
0
-2,863
-5,518
-5,336
-3,499
-1,319
-694
-309
-93
-82
-39
-56
-37
-33
-71
-190
-373
-167
0
0
0
0
0
0
0
0
0
0
0
0
0
14
13
12
-500
-1,000
0
0
0
0
7
2
270000-1,000-5001213140000000000000-167-373-190-71-33-37-56-39-82-93-309-694-1,319-3,499-5,336-5,518-2,86300000000-9,465-7,24400000000000000000000000000000-170000-5700-56-24-250-2500
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
481
707
0
0
00707481000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
314
297
280
262
245
417
0
0
0
41
35
27
21
14
264
211
0
106
0
0
001060211264142127354100041724526228029731400000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
47
0
5,519
0
9,820
8,554
7,942
7,052
6,081
4,694
15,199
14,590
15,311
13,697
30,411
27,469
33,002
32,334
26,531
22,688
26,820
20,057
16,678
18,661
13,813
7,585
7,585
19,473
16,630
14,148
11,177
8,176
5,154
3,053
1,108
402
402
406
40
6,797
7
-4,924
-285
-684
-3,670
-120
2,595
2,045
1,284
0
-4,957
-2,429
-4,127
-1,455
-4,334
-4,658
-3,228
613
826
1,112
1,019
548
243
4,653
4,220
3,570
2,861
9,679
8,858
26,757
25,663
24,857
22,859
21,313
19,206
16,476
15,002
11,875
8,461
36,126
31,185
29,070
24,933
22,281
19,013
15,772
12,524
8,541
2,802
-2,569
-7,339
-9,727
-10,531
-11,563
-11,563-10,531-9,727-7,339-2,5692,8028,54112,52415,77219,01322,28124,93329,07031,18536,1268,46111,87515,00216,47619,20621,31322,85924,85725,66326,7578,8589,6792,8613,5704,2204,6532435481,0191,112826613-3,228-4,658-4,334-1,455-4,127-2,429-4,95701,2842,0452,595-120-3,670-684-285-4,92476,797404064024021,1083,0535,1548,17611,17714,14816,63019,4737,5857,58513,81318,66116,67820,05726,82022,68826,53132,33433,00227,46930,41113,69715,31114,59015,1994,6946,0817,0527,9428,5549,82005,519047
   Retained Earnings -218,123-216,563-214,696-209,252-203,200-196,343-188,254-183,182-179,486-175,059-170,874-166,873-162,140-158,902-152,702-147,857-144,031-140,421-138,612-133,882-131,256-128,272-125,523-122,936-121,368-119,078-116,726-115,128-114,322-113,179-112,677-111,953-111,533-110,993-110,870-110,697-110,874-112,262-112,642-111,892-108,698-109,810-108,044-110,543-110,543-104,031-103,267-102,665-105,380-108,886-105,742-105,396-108,813-103,926-103,926-101,357-100,991-101,163-101,163-100,225-97,979-95,369-92,125-88,683-84,379-81,371-78,169-71,502-71,502-65,114-60,120-55,920-52,399-45,297-40,897-36,273-31,525-25,492-23,133-21,107-18,117-16,583-13,617-11,129-9,814-9,105-7,402-6,525-6,039-5,3960-4,02100
   Accumulated Other Comprehensive Income 
0
0
-109
0
-170
-163
-162
-162
-353
-337
10,096
10,815
12,925
12,898
21,438
21,073
22,232
25,487
28,625
5,850
30,851
5,850
5,850
5,851
5,850
5,850
5,850
1,243
1,213
1,243
1,243
1,243
1,158
1,243
1,243
1,000
1,243
1,243
1,243
1,000
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,000
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,243
1,237
1,2371,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,2431,0001,2431,2431,2431,2431,2431,2431,2431,2431,2431,0001,2431,2431,2431,0001,2431,2431,1581,2431,2431,2431,2131,2435,8505,8505,8505,8515,8505,85030,8515,85028,62525,48722,23221,07321,43812,89812,92510,81510,096-337-353-162-162-163-1700-10900
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,863
38,021
0
0
0
0
0
0
0
0
39,210
39,525
39,951
41,001
41,588
41,597
41,607
41,616
41,685
41,698
41,826
41,895
42,134
42,231
42,885
43,631
43,837
44,019
45,127
45,118
44,934
45,453
47,453
47,788
48,271
48,683
49,226
49,112
49,234
49,830
51,132
52,049
53,214
53,631
54,630
56,593
0
57,866
60,381
0
0
0060,38157,866056,59354,63053,63153,21452,04951,13249,83049,23449,11249,22648,68348,27147,78847,45345,45344,93445,11845,12744,01943,83743,63142,88542,23142,13441,89541,82641,69841,68541,61641,60741,59741,58841,00139,95139,52539,2100000000038,02137,8630000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue21,642
Cost of Revenue-1,282
Gross Profit20,36020,360
 
Operating Income (+$)
Gross Profit20,360
Operating Expense-33,365
Operating Income-13,005-13,005
 
Operating Expense (+$)
Research Development57
Selling General Administrative20,585
Selling And Marketing Expenses12,123
Operating Expense33,36532,765
 
Net Interest Income (+$)
Interest Income479
Interest Expense-3,394
Other Finance Cost-22
Net Interest Income-2,893
 
Pretax Income (+$)
Operating Income-13,005
Net Interest Income-2,893
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-16,339-9,671
EBIT - interestExpense = -16,686
-16,339
-12,945
Interest Expense3,394
Earnings Before Interest and Taxes (EBIT)-13,292-12,945
Earnings Before Interest and Taxes (EBITDA)-13,005
 
After tax Income (+$)
Income Before Tax-16,339
Tax Provision-0
Net Income From Continuing Ops-20,220-16,339
Net Income-16,339
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses34,647
Total Other Income/Expenses Net-3,3342,893
 

Technical Analysis of Fennec Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Fennec Pharmaceuticals Inc. The general trend of Fennec Pharmaceuticals Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Fennec Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Fennec Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 9.4 < 11.49 < 11.92.

The bearish price targets are: 8.59 > 8.46 > 7.44.

Tweet this
Fennec Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Fennec Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Fennec Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Fennec Pharmaceuticals Inc. The current macd is -0.19579471.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Fennec Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Fennec Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Fennec Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Fennec Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartFennec Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Fennec Pharmaceuticals Inc. The current adx is 29.15.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Fennec Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Fennec Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Fennec Pharmaceuticals Inc. The current sar is 10.68.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Fennec Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Fennec Pharmaceuticals Inc. The current rsi is 32.22. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Fennec Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartFennec Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Fennec Pharmaceuticals Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Fennec Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Fennec Pharmaceuticals Inc Daily Stochastic Oscillator ChartFennec Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Fennec Pharmaceuticals Inc. The current cci is -181.71641791.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Fennec Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartFennec Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Fennec Pharmaceuticals Inc. The current cmo is -52.86054477.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Fennec Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartFennec Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Fennec Pharmaceuticals Inc. The current willr is -88.72180451.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Fennec Pharmaceuticals Inc Daily Williams %R ChartFennec Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Fennec Pharmaceuticals Inc. The current atr is 0.45799475.

Fennec Pharmaceuticals Inc Daily Average True Range (ATR) ChartFennec Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Fennec Pharmaceuticals Inc. The current obv is 1,654,708.

Fennec Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartFennec Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Fennec Pharmaceuticals Inc. The current mfi is 13.62.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Fennec Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartFennec Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Fennec Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Fennec Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Fennec Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.219
Ma 20Greater thanMa 5010.529
Ma 50Greater thanMa 10010.059
Ma 100Greater thanMa 20010.059
OpenGreater thanClose9.340
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Fennec Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Fennec Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Fennec Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Fennec Pharmaceuticals Inc

I send you an email if I find something interesting about Fennec Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Fennec Pharmaceuticals Inc.

Receive notifications about Fennec Pharmaceuticals Inc in your mailbox!